Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients

Inclusion Criteria: * \- Patients with malignant haemopathy who received chemotherapy likely to lead to severe neutropenia (PN\<500/mm3) for a foreseeable period of 10 days. * Patients aged 14 years or older (no upper age limit) * Patients with malignant haemopathy who received an autologous marrow graft. * Patients with severe idiopathic medullar aplasia (PN\<500/mm3) who need to be hospitalised for at least 10 days consecutively (with or without immunosuppressant treatment). * Patients who have provided written informed consent to participate in this study. Exclusion Criteria: * Patients who received an allograft of marrow or hematopoietic stem cell transplant (given that these patients carry a risk of aspergillosis, which in most cases appears after medullar recovery, they will not be included in the study). * Patients who received an autologous hematopoietic stem cell transplant (given that the duration of the neutropenia is often less than 10 days). * Patients who do not meet the inclusion criteria * Persons not covered by the national Health Insurance Agency